

Public Declaration of Interests The European Patients' Forum Board Members

Public Declaration of Interests

١,

Name: Elisabeth Kasilingam

Organisation: European Multiple Sclerosis Platform

Country: Belgium

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in healthcare industries are those listed below:

Please indication N/A (Not applicable) as appropriate

2.1 Employment in the healthcare industry

Period	Company	Job title
N/A		

2.2 Consultancy

• Consultancy to a company shall mean: any activity where the board member provides advice (including training on a one to one basis) to a company regardless of contractual arrangements or any form of remuneration.

Period	Company	Subject Matter
2018	Roche	Member of the expert panel for the initiative "FutureProofing Healthcare: The Sustainability Index"

2.3. Consultancy/advisory role on patient-related activities in the last year

• The board member provides advice or participates in consultations regarding patient-related activities of a company that are strictly non-commercial (e.g. educational seminars, preparation and participation in patient meetings/trainings, development of non-product

European Patients' Forum • Chaussée d'Etterbeek, 180 • 1040 Brussels • Belgium Office Phone Number: +32 (0) 2 280 23 34 • Email: info@eu-patient.eu • www.eu-patient.eu

A STRONG PATIENTS' VOICE TO DRIVE BETTER HEALTH IN EUROPE



patient specific materials, participation in trainings of a company staff on patient-centricity etc.)

Strategic

Period	Company	Subject Matter
N/A		

Advisory Role

Strategic advisory role for a company shall mean: any activity where the board members participating (with a right to vote/influence the outputs) in a(n) (scientific) advisory board/steering committee with the role of providing advice/expressing opinions on the (future) strategy, direction and development activities of a healthcare company, either in terms of general strategy or product related strategy, regardless of contractual arrangements or any form of remuneration.

Period	Company	Product	Therapeutic Indication
N/A			

2.4 Financial Interests

Period	Company	Subject Matter
N/A		

2.5 Principal Investigator

Period	Company	Subject Matter
N/A		

2.6 Investigator

Period	Company	Subject Matter
N/A		

2.7 Grant / Funding to Organisation /Institution in 2016 (This is the organisation which nominated you to become a member of EPF)

Company	Subject Matter and amount



Actelion	€ 10,000 – EMSP project/activities 2017
	C 10,000 EMBI Project/ activities 2017
Almirall	€ 12,000 – EMSP project/activities 2017
Bayer	€ 50,000 - EMSP project/activities 2017
Biogen	€ 265,000 - EMSP project/activities 2017
Icometrix	€ 3,000 - EMSP project/activities 2017
MedDay	€ 15,000 - EMSP project/activities 2017
Merck	€ 150,000 - EMSP project/activities 2017
Mylan	€ 10,000 - EMSP project/activities 2017
Novartis	€ 105,000 - EMSP project/activities 2017
Roche	€ 120,000 - EMSP project/activities 2017
Sanofi	€ 128,850 - EMSP project/activities 2017
SCA	€ 5,000 - EMSP project/activities
Servier	€ 10,000 - EMSP project/activities
Synthon	€ 5,000 - EMSP project/activities
TEVA	€ 100,000 - EMSP project/activities
I	

2.8 Close Family Member Interest

Period	Company	Interest
N/A		

2.9 Any Other Interests or Facts

N/A



I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EPF website.

Full Name	Elisabeth Kasilingam
Date	01/08/2018